Literature DB >> 27465194

Malignant Melanoma: Beyond the Basics.

Sabrina N Pavri1,2, James Clune1,2, Stephan Ariyan1,2, Deepak Narayan1,2.   

Abstract

LEARNING
OBJECTIVES: After reading this article, the participant should be able to: 1. Discuss the initial management of cutaneous malignant melanoma with regard to diagnostic biopsy and currently accepted resection margins. 2. Be familiar with the management options for melanoma in specific situations such as subungual melanoma, auricular melanoma, and melanoma in the pregnant patient. 3. Discuss the differentiating characteristics of desmoplastic melanoma and its treatment options. 4. List the indications for sentinel lymph node biopsy and be aware of the ongoing trials and current literature. 5. Discuss the medical therapies available to patients with metastatic melanoma.
SUMMARY: Management of the melanoma patient is a complex and evolving subject. Plastic surgeons should be aware of the recent changes in the field. Excisional biopsy remains the gold standard for diagnosis, although there is no evidence that use of other biopsy types alters survival or recurrence. Wide local excisions should be carried out with margins as recommended by National Comprehensive Cancer Network guidelines according to lesion Breslow depth, with sentinel lymph node biopsy being offered to all medically suitable candidates with intermediate thickness melanomas (1.0 to 4.0 mm), and with sentinel lymph node biopsy being considered for high-risk lesions (ulceration and/or high mitotic figures) with melanomas of 0.75 to 1.0 mm. Melanomas diagnosed during pregnancy can be treated with preoperative lymphoscintigraphy and wide local excision under local anesthesia, with sentinel lymph node biopsy under general anesthesia delayed until after delivery. Management of desmoplastic melanoma is currently controversial with regard to the indications for sentinel lymph node biopsy and the efficacy of postoperative radiation therapy. Subungual and auricular melanoma have evolved from being treated by amputation of the involved appendage to less radical procedures-ear reconstruction is now attempted in the absence of gross invasion into the perichondrium, and subungual melanomas may be treated with wide local excision down to and including the periosteum, with immediate full-thickness skin grafting over bone. Although surgical treatment remains the current gold standard, recent advances in immunotherapy and targeted molecular therapy for metastatic melanoma show great promise for the development of medical therapies for melanoma.

Entities:  

Mesh:

Year:  2016        PMID: 27465194     DOI: 10.1097/PRS.0000000000002367

Source DB:  PubMed          Journal:  Plast Reconstr Surg        ISSN: 0032-1052            Impact factor:   4.730


  44 in total

1.  Alterations in patient plasma microRNA expression profiles following resection of metastatic melanoma.

Authors:  Nicholas Latchana; Mallory J DiVincenzo; Kelly Regan; Zachary Abrams; Xiaoli Zhang; Naduparambil K Jacob; Alejandro A Gru; Paolo Fadda; Joseph Markowitz; J Harrison Howard; William E Carson
Journal:  J Surg Oncol       Date:  2018-08-21       Impact factor: 3.454

Review 2.  Advances in engineering local drug delivery systems for cancer immunotherapy.

Authors:  Peter Abdou; Zejun Wang; Qian Chen; Amanda Chan; Daojia R Zhou; Vivienne Gunadhi; Zhen Gu
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2020-04-07

3.  Clinical significance of prognostic nutritional index (PNI) in malignant melanoma.

Authors:  Cem Mirili; Ali Yılmaz; Serkan Demirkan; Mehmet Bilici; Salim Basol Tekin
Journal:  Int J Clin Oncol       Date:  2019-05-09       Impact factor: 3.402

4.  Melanoma-Induced Reprogramming of Schwann Cell Signaling Aids Tumor Growth.

Authors:  Galina V Shurin; Oleg Kruglov; Fei Ding; Yan Lin; Xingxing Hao; Anton A Keskinov; Zhaoyang You; Anna E Lokshin; William A LaFramboise; Louis D Falo; Michael R Shurin; Yuri L Bunimovich
Journal:  Cancer Res       Date:  2019-03-26       Impact factor: 12.701

Review 5.  The Challenging Melanoma Landscape: From Early Drug Discovery to Clinical Approval.

Authors:  Mariana Matias; Jacinta O Pinho; Maria João Penetra; Gonçalo Campos; Catarina Pinto Reis; Maria Manuela Gaspar
Journal:  Cells       Date:  2021-11-09       Impact factor: 6.600

6.  A Novel Pyroptosis-Related lncRNA Signature for Predicting the Prognosis of Skin Cutaneous Melanoma.

Authors:  Jiaheng Xie; Haobo Li; Liang Chen; Yuan Cao; Yiming Hu; Zhechen Zhu; Ming Wang; Jingping Shi
Journal:  Int J Gen Med       Date:  2021-10-08

7.  Characterization of m6A-Related Genes Landscape in Skin Cutaneous Melanoma to Aid Immunotherapy and Assess Prognosis.

Authors:  Jinzhi Meng; Xing Huang; Yue Qiu; Miao Yu; Jinfeng Lu; Jun Yao
Journal:  Int J Gen Med       Date:  2021-09-07

8.  Identification of Hub Genes Associated With Melanoma Development by Comprehensive Bioinformatics Analysis.

Authors:  Jie Jiang; Chong Liu; Guoyong Xu; Tuo Liang; Chaojie Yu; Shian Liao; Zide Zhang; Zhaojun Lu; Zequn Wang; Jiarui Chen; Tianyou Chen; Hao Li; Xinli Zhan
Journal:  Front Oncol       Date:  2021-04-12       Impact factor: 6.244

Review 9.  Actin-Binding Proteins as Potential Biomarkers for Chronic Inflammation-Induced Cancer Diagnosis and Therapy.

Authors:  Yu-Gui Zhang; Jiang-Tao Niu; Hong-Wei Wu; Xin-Lei Si; Shu-Juan Zhang; Dong-Hui Li; Tian-Tian Bian; Yue-Feng Li; Xing-Ke Yan
Journal:  Anal Cell Pathol (Amst)       Date:  2021-06-05       Impact factor: 2.916

10.  Pure and Mixed Desmoplastic Melanomas: A Retrospective Clinicopathologic Comparison of 33 Cases.

Authors:  Sherman Chu; Kory P Schrom; Raghav Tripathi; Rosalynn R Z Conic; Harib H Ezaldein; Jeffrey F Scott; Kord Honda
Journal:  Am J Dermatopathol       Date:  2021-11-01       Impact factor: 1.319

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.